These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36077008)

  • 1. Pancancer Analysis of the Oncogenic and Prognostic Role of
    Liu Q; Xie R; Li Y
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.
    Wang Y; Zhang Y; Wang F; Li T; Song X; Shi H; Du J; Zhang H; Jing H; Han J; Tong D; Zhang J
    Sci Rep; 2022 Nov; 12(1):18518. PubMed ID: 36323715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
    Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
    Front Immunol; 2022; 13():903461. PubMed ID: 35663977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis of G6PD carcinogenesis in human tumors.
    Liu B; Fu X; Du Y; Feng Z; Chen R; Liu X; Yu F; Zhou G; Ba Y
    Carcinogenesis; 2023 Aug; 44(6):525-534. PubMed ID: 37335542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis.
    Wang C; Jiang X; Zhao Q; Xie Z; Cai H
    Biomed Rep; 2023 Nov; 19(5):77. PubMed ID: 37829257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
    Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
    Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
    Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets.
    Fu X; Ji F; He Q; Qiu X
    J Immunol Res; 2022; 2022():5826741. PubMed ID: 35791393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
    Li L; Feng Q; Wang X
    Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and immunological role of Asporin across cancers and exploration in bladder cancer.
    Wei F; Li T; Li J; Zhang Y; Liu T; Zhao Z; Zhu W; Guo H; Yang R
    Gene; 2023 Aug; 878():147573. PubMed ID: 37336272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
    Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
    Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors.
    Zhang Z; Wang Z; Liu Y; Zhao L; Fu W
    J Environ Pathol Toxicol Oncol; 2023; 42(2):11-30. PubMed ID: 36749087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Pan-Cancer Analysis of the Tumorigenic Effect of Leucine-Zipper-Like Transcription Regulator (LZTR1) in Human Cancer.
    Zhou B; Ying X; Chen Y; Cai X
    Oxid Med Cell Longev; 2022; 2022():2663748. PubMed ID: 36304963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of Voltage-Dependent Anion Channel (VDAC1) as a Cancer Therapeutic Target or Diagnostic Biomarker.
    Wang Z; Cheng Y; Song Z; Zhao R
    Dis Markers; 2022; 2022():5946110. PubMed ID: 35958281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of the novel omicron receptor AXL in cancers.
    Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.